As Invokana Lawsuit Filings Rise Concern Grows Over Potential Stroke Or Heart Attack Side Effect Risks

May 14, 2016 – – TheProductLawyers.com comments on the indications of heart attack risk for Invokana as yet another potential side effect of the drug. Use of Invokana, an SGLT2 inhibitor class medication, during clinical trials, raised concern about this risk. The exact role of Invokana in patient cardiac events has not been experimentally confirmed.

Since Invokana’s FDA approval in March 2013 focused attention has been paid to the drug’s cardiac side effects. In the course of clinical trials, it was reported, 13 patients experienced strokes, suffered heart attacks, or had other major cardiac events. These events happened uniformly within the first 30 days of treatment with Invokana. After 30 days, the risk level changed, becoming comparable to that experienced when taking placebo — an inert pill.

The New York Times noted that the drug label did not indicate a heart attack or stroke risk and that the FDA had ordered five post-marketing studies including a clinical trial to evaluate that risk.

Other diabetes drugs besides Invokana have had suspected heart risks. Avandia was banned in Europe and heavily restricted in the U.S. after being apparently linked to increased heart attack risk in 2010. Researchers suspect that Invokana may increase cholesterol. They don’t know whether this could be at the root of the “first month” cardiac event risk. Diabetes patients, for whom this medication is designed, are said to have a higher risk of heart disease and stroke. Also, when diabetics experience heart attacks, they are generally more serious than for those without the condition.

When blood flow is restricted to the heart, generally by blood clots, a heart attack happens. Without the needed oxygen from blood flow, heart muscle death starts to occur. Damage to the tissue follows, and if it is severe enough the heart muscle can be rendered too weak to effectively pump blood throughout the body.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009935